Showing 1 – 20 of 217
Relevance | Newest | Oldest |
  • JAMA January 15, 2014

    Figure: Researchers Probe the Aging Brain in Health and Disease

    Scientists are exploring how changes that normally occur in the aging brain compare with those occurring in brains affected by Alzheimer disease and other types of neurodegeneration.
  • JAMA December 26, 2012

    Figure: New Research on Alzheimer Treatments Ventures Beyond Plaques and Tangles

    In a healthy brain, microglial cells and astrocytes release molecules that keep the brain running smoothly. In Alzheimer disease, microglia and astrocytes can become dysregulated, causing detrimental neuroinflammation that can promote the development and progression of neurodegeneration.
  • JAMA March 2, 2011

    Figure: Scientists Probe Strategies to Repair Neuron Damage in Multiple Sclerosis

    Demyelination of axons contributes to neurodegeneration in patients with multiple sclerosis. Scientists are probing therapies that might restore neurons to healthy myelination.
  • Age Reversal

    Abstract Full Text
    JAMA. 2011; 305(5):458-458. doi: 10.1001/jama.2011.54
  • Preventing Neurodegeneration

    Abstract Full Text
    JAMA. 2007; 298(7):731-731. doi: 10.1001/jama.298.7.731-a
  • Mosquitoes and Malaria

    Abstract Full Text
    JAMA. 2003; 289(10):1234-1234. doi: 10.1001/jama.289.10.1234-a
  • NERVE DEGENERATION IN CHRONIC ARSENIC, LEAD, AND ALCOHOLIC POISONING.

    Abstract Full Text
    JAMA. 1890; XV(17):605-606. doi: 10.1001/jama.1890.02410430013001f
  • Nerve Wounds: Symptomatology of Peripheral Nerve Lesions Caused by War Wounds.

    Abstract Full Text
    JAMA. 1918; 71(15):1243-1243. doi: 10.1001/jama.1918.02600410065022
  • Therapy for Rare Nerve Cell Disease

    Abstract Full Text
    JAMA. 2017; 317(21):2157-2157. doi: 10.1001/jama.2017.6334
  • Surgical and Mechanical Treatment of Peripheral Nerves.

    Abstract Full Text
    JAMA. 1922; 79(6):495-496. doi: 10.1001/jama.1922.02640060077033
  • Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial

    Abstract Full Text
    free access has multimedia
    JAMA. 2013; 309(19):2005-2015. doi: 10.1001/jama.2013.4997
    To determine if adding carotenoids and omega-3 fatty acids to the Age-Related Eye Disease Study (AREDS) formulation decreases risk of age-related macular degeneration (AMD) progression, 4203 patients in the AREDS2 trial at risk of developing advanced AMD were randomized to receive the AREDS formulation with lutein + zeaxanthin, docosahexaenoic acid + eicosapentaenoic acid, or both.
  • Age-Related Macular Degeneration

    Abstract Full Text
    free access
    JAMA. 2012; 308(16):1702-1702. doi: 10.1001/jama.2012.4091
  • Diagnostic Electromyography

    Abstract Full Text
    JAMA. 1967; 199(10):727-731. doi: 10.1001/jama.1967.03120100089017
  • DEGENERATION AND REGENERATION OF NERVE ENDINGS IN VOLUNTARY MUSCLE.

    Abstract Full Text
    JAMA. 1900; XXXIV(7):437-437. doi: 10.1001/jama.1900.02460070053013
  • The Pathophysiology and Treatment of Glaucoma: A Review

    Abstract Full Text
    free access has multimedia
    JAMA. 2014; 311(18):1901-1911. doi: 10.1001/jama.2014.3192

    In a review of articles published between January 2000 and September 2013, Weinreb and coauthors describe the pathophysiology and glaucoma and recommend early referral of patients with a family history or suspicious optic nerve for ophthalmologic examination.

  • Human Neuroanatomy

    Abstract Full Text
    JAMA. 1953; 153(12):1138-1138. doi: 10.1001/jama.1953.02940290070052
  • Physiology in Health and Disease

    Abstract Full Text
    JAMA. 1945; 127(4):251-251. doi: 10.1001/jama.1945.02860040061025
  • Age-Related Macular Degeneration

    Abstract Full Text
    JAMA. 2006; 295(20):2438-2438. doi: 10.1001/jama.295.20.2438
  • A 76-Year-Old Man With Macular Degeneration

    Abstract Full Text
    is expired quiz
    JAMA. 2006; 295(20):2394-2406. doi: 10.1001/jama.295.20.2394
  • JAMA May 24, 2006

    Figure 1: Macula Lutea and Ocular Structures With Age-Related Macular Degeneration (AMD)

    A, Fundus photograph of normal retina.The macula is the central part of the retina delimited by the superior temporal and inferior temporal retinal vascular arcades. The fovea is about the size of the optic nerve (diameter, 1500 μm) and is centered on the foveola (diameter, 350 μm). The foveola is the thinnest part of the retina. It is devoid of ganglion cells and is responsible for the most acute detailed vision. B, Cross section of normal retina, choroid, and sclera. A photon of light must penetrate all of the layers of the retina before being absorbed and converted into a neural signal by the photoreceptor outer segments. This retinal transparency results from the structured organization and orientation of the retinal cell bodies and processes. The retinal photoreceptors and retinal pigment epithelium (RPE) are metabolically active cells that depend on the choroidal vasculature to supply oxygen and nutrients and remove metabolic waste. C, Dry AMD or nonneovascular AMD is characterized by nodular, hard drusen, with sharp edges, diffuse soft drusen, and RPE hyperplasia and hyperpigmentation. Histologically, drusenoid material is found between the RPE and the RPE basement membrane (basal laminar deposits) and/or between the RPE basement membrane and the collagenous layer of Bruch membrane (basal linear deposits). The risk for progression to wet or neovascular AMD increases with increasing number and size of drusen and the presence of RPE pigmentary abnormalities. Wet AMD or neovascular AMD is characterized by the intrusion of abnormal new vessels from the choroid into the subretinal (type 2) and/or sub-RPE (type 1) space. In some cases, neovascularization may originate from the retinal vessels (not shown), with or without a choroidal component. Choroidal neovascularization often exudes fluid and/or hemorrhage into the subretinal and/or sub-RPE space.